1
|
Abstract
PURPOSE Previous studies has demonstrated the utility of human epidermal growth factor receptor type 2 (HER2) as an attractive target for cancer molecular imaging and therapy. An affibody protein with strong binding affinity for HER2, ZHER2:342, has been reported. Various methods of chelator conjugation for radiolabeling HER2 affibody molecules have been described in the literature including N-terminal conjugation, C-terminal conjugation, and other methods. Cu-64 has recently been extensively evaluated due to its half-life, decay properties, and availability. Our goal was to optimize the radiolabeling method of this affibody molecule with Cu-64, and translate a positron emission tomography (PET) probe with the best in vivo performance to clinical PET imaging of HER2-positive cancers. PROCEDURES In our study, three anti-HER2 affibody proteins-based PET probes were prepared, and their in vivo performance was evaluated in mice bearing HER2-positive subcutaneous SKOV3 tumors. The affibody analogues, Ac-Cys-ZHER2:342, Ac-ZHER2:342(Cys39), and Ac-ZHER2:342-Cys, were synthesized using the solid phase peptide synthesis method. The purified small proteins were site-specifically conjugated with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris- aceticacid-10-maleimidethylacetamide (maleimido-mono-amide-DOTA). The resulting DOTA-affibody conjugates were then radiolabeled with Cu-64. Cell uptake assay of the resulting PET probes, [64Cu]DOTA-Cys-ZHER2:342, [64Cu]DOTA-ZHER2:342(Cys39), and [64Cu]DOTA-ZHER2:342-Cys, was performed in HER2-positive human ovarian SKOV3 carcinoma cells at 4 and 37 °C. The binding affinities of the radiolabeled peptides were tested by cell saturation assay using SKOV3 cells. PET imaging, biodistribution, and metabolic stability studies were performed in mice bearing SKOV3 tumors. RESULTS Cell uptake assays showed high and specific uptake by incubation of Cu-64-labeled affibodies with SKOV3 cells. The affinities (KD) of the PET radio probes as tested by cell saturation analysis were in the low nanomolar range with the ranking of [64Cu]DOTA-Cys-ZHER2:342 (25.2 ± 9.2 nM) ≈ [64Cu]DOTA-ZHER2:342-Cys (32.6 ± 14.7 nM) > [64Cu]DOTA-ZHER2:342(Cys39) (77.6 ± 22.2 nM). In vitro stability and in vivo metabolite analysis study revealed that all three probes were stable enough for in vivo imaging applications, while [64Cu]DOTA-Cys-ZHER2:342 showed the highest stability. In vivo small-animal PET further demonstrated fast tumor targeting, good tumor accumulation, and good tumor to normal tissue contrast of all three probes. For [64Cu]DOTA-Cys-ZHER2:342, [64Cu]DOTA-ZHER2:342(Cys39), and [64Cu]DOTA-ZHER2:342-Cys, tumor uptake at 24 h are 4.0 ± 1.0 % ID/g, 4.0 ± 0.8 %ID/g, and 4.3 ± 0.7 %ID/g, respectively (mean ± SD, n = 4). Co-injection of the probes with non-labeled anti-HER2 affibody proteins confirmed in vivo specificities of the compounds by tumor uptake reduction. CONCLUSIONS The three Cu-64-labeled ZHER2:342 analogues all display excellent HER2 targeting ability and tumor PET imaging quality. Although varied in the position of the radiometal labeling of these three Cu-64-labeled ZHER2:342 analogues, there is no significant difference in tumor and normal tissue uptakes among the three probes. [64Cu]DOTA-Cys-ZHER2:342 stands out as the most superior PET probe because of its highest affinities and in vivo stability.
Collapse
Affiliation(s)
- Shibo Qi
- School of Environmental and Chemical Engineering, Tianjin Polytechnic University, Tianjin, 300387, China.,Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305-5344, USA
| | - Susan Hoppmann
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305-5344, USA
| | - Yingding Xu
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305-5344, USA
| | - Zhen Cheng
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305-5344, USA.
| |
Collapse
|
2
|
Li P, Hoppmann S, Du P, Li H, Evans PM, Moestue SA, Yu W, Dong F, Liu H, Liu L. Pharmacokinetics of Perfluorobutane after Intra-Venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers. Ultrasound Med Biol 2017; 43:1031-1039. [PMID: 28283327 DOI: 10.1016/j.ultrasmedbio.2017.01.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 12/22/2016] [Accepted: 01/06/2017] [Indexed: 06/06/2023]
Abstract
Sonazoid is an ultrasound contrast agent based on microbubbles (MB) containing perfluorobutane (PFB) gas. Sonazoid is approved in Japan, Korea and Norway for contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions (Japan only). The objective of this study was to determine the pharmacokinetics (PKs) and safety of Sonazoid in Chinese healthy volunteers (HVs) and to evaluate the potential for ethnic differences in PKs between Chinese and Caucasian HVs. Sonazoid was administered as an intra-venous bolus injection at the clinical dose of 0.12 μL or 0.60 μL MB/kg body weight to two groups of eight Chinese HVs. Expired air and blood samples were collected and analyzed using a validated gas chromatographic tandem mass spectrometry method, and the main PK parameters were calculated. The highest PFB concentrations in blood were observed shortly after intra-venous administration of Sonazoid, and elimination of PFB was rapid. In the 0.12 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for only 10 to 15 min post-injection. In the 0.60 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for 60 min post-injection, and the shape of the elimination curve suggested a biphasic elimination profile. The maximum observed concentration (Cmax) values of PFB in blood were 2.3 ± 1.1 and 19.1 ± 9.2 ng/g for the 0.12 and 0.60 μL MB/kg body weight dose groups (mean ± standard deviation). Area under the curve values were 10.1 ± 2.7 and 90.1 ± 38.3 ng × min/g for the 0.12 and 0.60 μL MB/kg body weight dose groups. Cmax values of PFB in exhaled air were 0.35 ± 0.2 and 2.4 ± 0.7 ng/mL for the 0.12 and 0.60 μL MB/kg body weight dose groups. Assessment of laboratory parameters, vital signs, oxygen saturation and electrocardiograms revealed no changes indicative of a concern. The PK profile and safety data generated in the Chinese HVs were comparable to previous data for Caucasian HVs.
Collapse
Affiliation(s)
- Pengfei Li
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Susan Hoppmann
- GE Healthcare, The Grove Centre, Amersham, Buckinghamshire, UK.
| | - Ping Du
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Huiling Li
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Paul M Evans
- GE Healthcare, The Grove Centre, Amersham, Buckinghamshire, UK
| | - Siver A Moestue
- Department of Laboratory Medicine, Women's and Children's Health, Faculty of Medicine, NTNU (Norwegian University of Science and Technology), Trondheim, Norway
| | - Weiyue Yu
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Fang Dong
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Hongchuan Liu
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| | - Lihong Liu
- Phase I Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, China
| |
Collapse
|
3
|
Hirani E, Daalsgard G, Hoppmann S, Evans P. Incorporation of safety pharmacology endpoints in the toxicological assessment of a potential diagnostic positron emission tomography (PET) imaging agent. J Pharmacol Toxicol Methods 2016. [DOI: 10.1016/j.vascn.2016.02.110] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Arulappu A, Battle M, Eisenblaetter M, McRobbie G, Khan I, Monypenny J, Weitsman G, Galazi M, Hoppmann S, Gazinska P, Wulaningsih W, Dalsgaard GT, Macholl S, Ng T. c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer. J Nucl Med 2016; 57:765-70. [PMID: 26635342 DOI: 10.2967/jnumed.115.164384] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2015] [Accepted: 11/13/2015] [Indexed: 12/28/2022] Open
Abstract
UNLABELLED Locoregional recurrence of breast cancer poses significant clinical problems because of frequent inoperability once the chest wall is involved. Early detection of recurrence by molecular imaging agents against therapeutically targetable receptors, such as c-Met, would be of potential benefit. The aim of this study was to assess (18)F-AH113804, a peptide-based molecular imaging agent with high affinity for human c-Met, for the detection of early-stage locoregional recurrence in a human basal-like breast cancer model, HCC1954. METHODS HCC1954 tumor-bearing xenograft models were established, and (18)F-AH113804 was administered. Distribution of radioactivity was determined via PET at 60 min after radiotracer injection. PET and CT images were acquired 10 d after tumor inoculation, to establish baseline distribution and uptake, and then on selected days after surgical tumor resection. CT images and caliper were used to determine the tumor volume. Radiotracer uptake was assessed by (18)F-AH113804 PET imaging. c-Met expression was assessed by immunofluorescence imaging of tumor samples and correlated with (18)F-AH113804 PET imaging results. RESULTS Baseline uptake of (18)F-AH113804, determined in tumor-bearing animals after 10 d, was approximately 2-fold higher in the tumor than in muscle tissue or the contralateral mammary fat pad. The tumor growth rate, determined from CT images, was comparable between the animals with recurrent tumors, with detection of tumors of low volume (<10 mm(3)) only possible by day 20 after tumor resection. (18)F-AH113804 PET detected local tumor recurrence as early as 6 d after surgery in the recurrent tumor-bearing animals and exhibited significantly higher (18)F-AH113804 uptake (in comparison to mammary fatty tissue), with a target-to-background (muscle) ratio of approximately 3:1 (P < 0.01). The c-Met expression of individual resected tumor samples, determined by immunofluorescence, correlated with the respective (18)F-AH113804 imaging signals (r = 0.82, P < 0.05). CONCLUSION (18)F-AH113804 PET provides a new diagnostic tool for the detection of c-Met-expressing primary tumor and has potential utility for the detection of locoregional recurrence from an early stage.
Collapse
Affiliation(s)
- Appitha Arulappu
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom
| | - Mark Battle
- GE Healthcare, Life Sciences, Amersham, United Kingdom
| | - Michel Eisenblaetter
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom Division of Imaging Sciences & Biomedical Engineering, King's College London, London, United Kingdom Department of Clinical Radiology, University Hospital Münster, Münster, Germany
| | | | - Imtiaz Khan
- GE Healthcare, Life Sciences, Amersham, United Kingdom
| | - James Monypenny
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom
| | - Gregory Weitsman
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom
| | - Myria Galazi
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom
| | | | - Patrycja Gazinska
- Breast Cancer NOW Unit, King's College London School of Medicine, London, United Kingdom
| | - Wulan Wulaningsih
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom
| | | | - Sven Macholl
- GE Healthcare, Life Sciences, Amersham, United Kingdom Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; and
| | - Tony Ng
- Richard Dimbleby Department of Cancer Research, Kings College London, London, United Kingdom Breast Cancer NOW Unit, King's College London School of Medicine, London, United Kingdom UCL Cancer Institute, University College London, London, United Kingdom
| |
Collapse
|
5
|
Glaser M, Iveson P, Hoppmann S, Indrevoll B, Wilson A, Arukwe J, Danikas A, Bhalla R, Hiscock D. Reply: Al18F Labeling of Affibody Molecules. J Nucl Med 2014; 55:1043-4. [DOI: 10.2967/jnumed.114.138206] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Trousil S, Hoppmann S, Nguyen QD, Kaliszczak M, Tomasi G, Iveson P, Hiscock D, Aboagye EO. Positron emission tomography imaging with 18F-labeled ZHER2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies. Clin Cancer Res 2014; 20:1632-43. [PMID: 24493830 DOI: 10.1158/1078-0432.ccr-13-2421] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Expression of HER2 has profound implications on treatment strategies in various types of cancer. We investigated the specificity of radiolabeled HER2-targeting ZHER2:2891 Affibody, [(18)F]GE-226, for positron emission tomography (PET) imaging. EXPERIMENTAL DESIGN Intrinsic cellular [(18)F]GE-226 uptake and tumor-specific tracer binding were assessed in cells and xenografts with and without drug treatment. Specificity was further determined by comparing tumor localization of a fluorescently labeled analogue with DAKO HercepTest. RESULTS [(18)F]GE-226 uptake was 11- to 67-fold higher in 10 HER2-positive versus HER2-negative cell lines in vitro independent of lineage. Uptake in HER2-positive xenografts was rapid with net irreversible binding kinetics making possible the distinction of HER2-negative [MCF7 and MCF7-p95HER2: NUV60 (%ID/mL) 6.1 ± 0.7; Ki (mL/cm(3)/min) 0.0069 ± 0.0014] from HER2-positive tumors (NUV60 and Ki: MCF7-HER2, 10.9 ± 1.5 and 0.015 ± 0.0035; MDA-MB-361, 18.2 ± 3.4 and 0.025 ± 0.0052; SKOV-3, 18.7 ± 2.4 and 0.036 ± 0.0065) within 1 hour. Tumor uptake correlated with HER2 expression determined by ELISA (r(2) = 0.78), and a fluorophore-labeled tracer analogue colocalized with HER2 expression. Tracer uptake was not influenced by short-term or continuous treatment with trastuzumab in keeping with differential epitope binding, but reflected HER2 degradation by short-term NVP-AUY922 treatment in SKOV-3 xenografts (NUV60: 13.5 ± 2.1 %ID/mL vs. 9.0 ± 0.9 %ID/mL for vehicle or drug, respectively). CONCLUSIONS [(18)F]GE-226 binds with high specificity to HER2 independent of cell lineage. The tracer has potential utility for HER2 detection, irrespective of prior trastuzumab treatment, and to discern HSP90 inhibitor-mediated HER2 degradation.
Collapse
Affiliation(s)
- Sebastian Trousil
- Authors' Affiliations: Comprehensive Cancer Imaging Centre at Imperial College, Faculty of Medicine, Imperial College London, London; and GE Healthcare, Medical Diagnostics, The Grove Centre, White Lion Road, Amersham, Buckinghamshire, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Trousil S, Hoppmann S, Nguyen QD, Kaliszczak M, Tomasi G, Iveson P, Hiscock D, Aboagye EO. Abstract B140: Positron emission tomography imaging of HER2 expression and pharmacodynamic response to HSP90 inhibition with the next-generation ZHER2:2891 Affibody molecule [18F]GE-226. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-b140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Accurate assessment of HER2 status remains a clinical challenge, with up to 20% of patients being potentially withdrawn from therapy or exposed to unnecessary toxicity. Non-invasive imaging is widely seen as a viable alternative to current methods, in particular in the setting of locoregional and distant recurrences not amenable to biopsy. A next-generation HER2-targeting Affibody-based radiotracer has been developed, [18F]GE-226, with enhanced pharmacokinetic characteristics and improved properties for large-scale and GMP grade synthesis. Kinetic modeling gave insights into Affibody-HER2 interactions.
Intrinsic affinity to HER2 (KD = 76 pM) resulted in 11 to 67-fold higher [18F]GE-226 uptake in ten HER2 positive versus negative cell lines in vitro independent of lineage. Uptake correlated with HER2 protein expression but was independent of presence of other targets like EGFR. Blocking with [19F]GE-226 and HER2 siRNA treatment reduced uptake by 96.8 ± 2.6% and 81.7 ± 9.2%, respectively. Uptake in HER2 positive xenografts was rapid with steady state net irreversible binding kinetics making possible the distinction of HER2 negative (MCF7 (n = 6) and MCF7-p95HER2 (n = 3): NUV60 (normalized uptake value at 60 min; %ID/mL) 6.1 ± 0.7; Ki (irreversible uptake rate; mL/cm3/min) 0.0069 ± 0.0014) from HER2 positive tumors (NUV60 and Ki: MCF7-HER2, 10.9 ± 1.5 and 0.015 ± 0.0035; MDA-MB-361, 18.2 ± 3.4 and 0.025 ± 0.0052; SKOV-3, 18.7 ± 2.4 and 0.036 ± 0.0065; all n = 6) within 1 h. Tumor uptake correlated with HER2 expression determined by ELISA (r2=0.78). Specificity was further determined by comparing tumor localization of a fluorescently labeled tracer analogue with DAKO HercepTest. Affibody signal co-localized with HER2 expression at the cellular level independent of spatial heterogeneity. Tracer binding was not influenced by short-term or continuous exposure to trastuzumab in SKOV-3 xenografts (n=6) in keeping with differential epitope binding. Inhibition of the chaperone HSP90– of which HER2 is a client protein– by the therapeutic development candidate NVP-AUY922 caused dose-dependent HER2 degradation and consequently reduced tracer uptake in SKOV-3 cells in vitro and xenografts in vivo (area under the curve, AUC0-60: 618.4±90.1 and 446.7±42.8 %ID/mL*min for vehicle (n=4) and drug (n=5), respectively; P=0.043).
In conclusion, [18F]GE-226 differentiates HER2 negative from HER2 expressing tumors. The tracer has potential utility for HER2 detection, irrespective of prior trastuzumab treatment and to monitor response to HSP90 inhibition. Lineage-independence of these results extends application beyond breast cancer. Due to the specific annotation to HER2, enhanced pharmacokinetic properties and completion of initial preclinical toxicology testing, [18F]GE-226 is now transitioning into clinical development.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B140.
Citation Format: Sebastian Trousil, Susan Hoppmann, Quang-Dé Nguyen, Maciej Kaliszczak, Giampaolo Tomasi, Peter Iveson, Duncan Hiscock, Eric O. Aboagye. Positron emission tomography imaging of HER2 expression and pharmacodynamic response to HSP90 inhibition with the next-generation ZHER2:2891 Affibody molecule [18F]GE-226. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B140.
Collapse
Affiliation(s)
| | - Susan Hoppmann
- 2Medical Diagnostics Discovery, GE Healthcare, Amersham, United Kingdom
| | | | | | | | - Peter Iveson
- 2Medical Diagnostics Discovery, GE Healthcare, Amersham, United Kingdom
| | - Duncan Hiscock
- 2Medical Diagnostics Discovery, GE Healthcare, Amersham, United Kingdom
| | | |
Collapse
|
8
|
Glaser M, Iveson P, Hoppmann S, Indrevoll B, Wilson A, Arukwe J, Danikas A, Bhalla R, Hiscock D. Three Methods for 18F Labeling of the HER2-Binding Affibody Molecule ZHER2:2891 Including Preclinical Assessment. J Nucl Med 2013; 54:1981-8. [DOI: 10.2967/jnumed.113.122465] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|
9
|
Hoppmann S, Iveson P, Glaser M, Indrevoll B, Macholl S, Battle M, Hiscock D. GE226: A Molecular Targeted PET Imaging Agent to Assess HER2 Status in Vivo. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt144.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Yang X, Hoppmann S, Liu H, Allegretta M, Chua MS, Cheng Z, So S. Abstract 715: Molecular imaging of hepatocellular carcinoma using radiolabeled monoclonal antibody PET probes targeting glypican-3. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Glypican-3 (GPC3) is a cell-surface protein which is over-expressed in more than 50% of hepatocellular carcinoma (HCC) patients, but is negligibly expressed in normal livers, benign liver lesions, and tissues adjacent to HCC. GPC3 is therefore a potential molecular target for HCC diagnosis.
Methods: Two radiotracers, 64Cu-DOTA-GPC3 and 89Zr-DFO-GPC3, were synthesized based on the human anti-GPC3 monoclonal antibody (MAb clone 1G12). These radiotracers were used for positron emission tomography (PET) imaging of subcutaneous or orthotopic HCC xenografts in nude mice, generated from HCC cell lines expressing high (HepG2), moderate (Hep3B), or low (PLC/PRF/5) levels of GPC3. Biodistribution analysis and tumor-to-liver ratios were calculated to assess the performance and specificity of these radiotracers.
Results: The anti-GPC3 MAb showed high binding affinity to recombinant human GPC3 protein in vitro (KD = 0.40 ± 0.04 nM), and specifically identified HCC cell lines and human specimens with high GPC3 expression. In vivo, 64Cu-DOTA-GPC3 showed significantly higher uptake in HepG2 xenografts (17.05 ± 1.31% ID/g) compared with non-specific 18F-fluoro-deoxy-glucose (18F-FDG) (3.17 ± 0.59% ID/g), and the non-targeting 64Cu-DOTA-IgG (5.10 ± 1.27% ID/g) at 72 h post-injection (p.i.) (p < 0.005). However, the tumor-to-liver ratio was only 0.46 ± 0.32 at 72 h p.i., due to high uptake of 64Cu-DOTA-GPC3 in the liver. To increase tumor-to-liver ratio, we synthesized the 89Zr-DFO-GPC3 radiotracer, which displayed specific cellular uptake in GPC3-positive cells in vitro, and also internalized over time in these cells. In vivo, 89Zr-DFO-GPC3 showed high and specific uptake in the subcutaneous HepG2 xenografts, but not in the non-HCC, GPC3-negative ones (PC3 and A375M). Consistently, in vivo biodistribution analysis demonstrated significantly higher uptake of 89Zr-DFO-GPC3 in HepG2 xenografts at 48 h p.i. (10.80 ± 1.69% ID/g, n=4) and 192 h p.i. (8.76 ± 1.12% ID/g, n=4), compared to 1.19 ± 0.27% ID/g in PC3 xenografts and 2.02 ± 0.58% ID/g in A375M xenografts at 192 h time point (p < 0.005) The tumor-to-liver ratios for HepG2 xenografts at 48 h and 192 h were 2.64 ± 0.20, and 4.10 ± 0.17, respectively. More importantly, 89Zr-DFO-GPC3 was able to delineate orthotopic HCC xenografts from the surrounding normal liver. Biodistribution analysis in these orthotopic xenografts showed uptake of 14.0 ± 2.50% ID/g for HepG2; 7.71 ± 1.64% ID/g for Hep3B; and 5.54 ± 1.00% ID/g for PLC/PRF/5 at 168 h p.i. The corresponding tumor-to-liver ratios were 6.65 ± 1.33 for HepG2, 6.15 ± 1.75 for PLC/PRF/5, and 4.29 ± 0.52 for Hep3B.
Conclusion: We demonstrate that anti-GPC3 MAb-based PET probes can detect GPC3-positive HCCs in subcutaneous and orthotopic animal models. Especially, 89Zr-DFO-GPC3 is a promising probe and clinically useful probe for the specific imaging of GPC3-positive HCCs.
Citation Format: Xiaoyang Yang, Susan Hoppmann, Hongguang Liu, Mark Allegretta, Mei-Sze Chua, Zhen Cheng, Samuel So. Molecular imaging of hepatocellular carcinoma using radiolabeled monoclonal antibody PET probes targeting glypican-3. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 715. doi:10.1158/1538-7445.AM2013-715
Collapse
Affiliation(s)
- Xiaoyang Yang
- 1Asian Liver Center, Dept. of Surgery, Stanford University, Stanford, CA
| | | | - Hongguang Liu
- 2Dept. of Radiology, Stanford University, Stanford, CA
| | | | - Mei-Sze Chua
- 1Asian Liver Center, Dept. of Surgery, Stanford University, Stanford, CA
| | - Zhen Cheng
- 2Dept. of Radiology, Stanford University, Stanford, CA
| | - Samuel So
- 1Asian Liver Center, Dept. of Surgery, Stanford University, Stanford, CA
| |
Collapse
|
11
|
Yang M, Hoppmann S, Chen L, Cheng Z. Human serum albumin conjugated biomolecules for cancer molecular imaging. Curr Pharm Des 2012; 18:1023-31. [PMID: 22272822 DOI: 10.2174/138161212799315830] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2011] [Accepted: 12/09/2011] [Indexed: 11/22/2022]
Abstract
Molecular imaging is a fast growing field in biomedical research. The discovery, development and continual improvement of molecular probes are important for ongoing research efforts in molecular imaging. Human serum albumin (HSA) offers favorable characteristics and opportunities as a platform protein for molecular imaging probe discovery and optimization. It has many advantages, including alternation of biodistribution and pharmacokinetic properties of molecular imaging probes, enhancing the blood half-life of bio-molecules, and making these molecules multivalent, all of which make HSA a promising carrier for cancer-targeted imaging and therapy. Numerous studies have focused on the development and application of HSA-based cancer imaging and treatment. This review gives a brief account of albumin-based molecular probes, focusing on their applications in cancer molecular imaging, such as PET/SPECT, MRI and optical imaging.
Collapse
Affiliation(s)
- Meng Yang
- Molecular Imaging Program at Stanford, Department of Radiology and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA 94305, USA
| | | | | | | |
Collapse
|
12
|
Hoppmann S, Danikas A, Durrant C, Iveson P, Glaser M, Indrevoll B, Hiscock D. Abstract 353: In vivo PET imaging of HER2 expression with GE226: An 18F-labelled affibody molecule. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The assessment of HER2 expression in biopsies from primary lesions of breast cancer patients is a standard procedure to select patients for HER2-targeted therapies. However, in metastatic disease in which HER2 status can change, determination of HER2 expression is not standard procedure, which complicates patient management. Herein we report evidence for GE226 ([18F]FBA-ZHER2:2891), a highly specific HER2 targeted imaging agent that can determine HER2 expression levels in preclinical tumour models. We propose that GE226 can be progressed to clinical development for non-invasive determination of the HER2 status in recurrent breast cancer patients to improve the clinical management and therapy selection. Methods: The highly selective HER2 targeted 18F-labelled Affibody molecule GE226 was characterized in a murine dual tumour breast cancer model bearing NCI-N87 (high HER2 status) and A431 (low HER2 status) xenografts in separate flanks. Tumour-bearing mice were injected with 3 to 10 MBq of GE226, followed by biodistribution or positron emission tomography (PET) imaging analysis. Results: Biodistribution analysis demonstrated good differentiation of GE226 retention between high and low HER2 expressing tumours (8.4% ID/g and 3.4% ID/g respectively, 30 min post injection). GE226 cleared quickly from background tissue, including kidneys, with excellent ratios for tumour-to-muscle (8.9 for high HER2 status tumours and 3.6 for low HER2 status tumours, 30 min post injection) and tumour-to-blood (2.5 for high HER2 status tumours and 1.0 for low HER2 status tumours, 30 min post injection). PET imaging of GE226 in the dual tumour mouse model showed a marked difference in signal intensity between the two tumour types. Conclusions: The highly selective HER2 targeted Affibody molecule GE226 can image different levels of HER2 expression in a dual-tumour preclinical model of breast cancer with good target-to-background ratios. These data compare favourably with previous patient SPECT and PET studies using the 111In- or 68Ga-labelled HER2-binding Affibody molecule ABY-002 (Baum et al., J Nucl Med. 2010;51(6):892-7) which supports the efficacy of this class of Affibody tracer for visualization of HER2 expressing metastases. We plan to progress GE226 further to assess HER2 status in metastatic breast cancer patients in clinical PET studies.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 353. doi:1538-7445.AM2012-353
Collapse
|
13
|
Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A, Cheng Z. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem 2011; 22:413-21. [PMID: 21299201 DOI: 10.1021/bc100432h] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Affibody molecules have received significant attention in the fields of molecular imaging and drug development. However, Affibody scaffolds display an extremely high renal uptake, especially when modified with chelators and then labeled with radiometals. This unfavorable property may impact their use as radiotherapeutic agents in general and as imaging probes for the detection of tumors adjacent to kidneys in particular. Herein, we present a simple and generalizable strategy for reducing the renal uptake of Affibody molecules while maintaining their tumor uptake. Human serum albumin (HSA) was consecutively modified by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono-N-hydroxysuccinimide ester (DOTA-NHS ester) and the bifunctional cross-linker sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1-carboxylate (Sulfo-SMCC). The HER2 Affibody analogue, Ac-Cys-Z(HER2:342), was covalently conjugated with HSA, and the resulting bioconjugate DOTA-HSA-Z(HER2:342) was further radiolabeled with ⁶⁴Cu and ¹¹¹In and evaluated in vitro and in vivo. Radiolabeled DOTA-HSA-Z(HER2:342) conjugates displayed a significant and specific cell uptake into SKOV3 cell cultures. Positron emission tomography (PET) investigations using ⁶⁴Cu-DOTA-HSA-Z(HER2:342) were performed in SKOV3 tumor-bearing nude mice. High tumor uptake values (>14% ID/g at 24 and 48 h) and high liver accumulations but low kidney accumulations were observed. Biodistribution studies and single-photon emission computed tomography (SPECT) investigations using ¹¹¹In-DOTA-HSA-Z(HER2:342) validated these results. At 24 h post injection, the biodistribution data revealed high tumor (16.26% ID/g) and liver (14.11% ID/g) uptake but relatively low kidney uptake (6.06% ID/g). Blocking studies with coinjected, nonlabeled Ac-Cys-Z(HER2:342) confirmed the in vivo specificity of HER2. Radiolabeled DOTA-HSA-Z(HER2:342) Affibody conjugates are promising SPECT and PET-type probes for the imaging of HER2 positive cancer. More importantly, DOTA-HSA-Z(HER2:342) is suitable for labeling with therapeutic radionuclides (e.g., ⁹⁰Y or ¹⁷⁷Lu) for treatment studies. The approach of using HSA to optimize the pharmacokinetics and biodistribution profile of Affibodies may be extended to the design of many other targeting molecules.
Collapse
Affiliation(s)
- Susan Hoppmann
- Molecular Imaging Program at Stanford (MIPS), Department of Radiology and Bio-X Program, Stanford University, Stanford, California, 94305, USA
| | | | | | | | | | | | | |
Collapse
|
14
|
Wolf S, Haase-Kohn C, Lenk J, Hoppmann S, Bergmann R, Steinbach J, Pietzsch J. Expression, purification and fluorine-18 radiolabeling of recombinant S100A4: a potential probe for molecular imaging of receptor for advanced glycation endproducts in vivo? Amino Acids 2010; 41:809-20. [DOI: 10.1007/s00726-010-0822-x] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Accepted: 11/26/2010] [Indexed: 01/27/2023]
|
15
|
Pietzsch J, Walther M, Bergmann R, Hoppmann S. MS43 COPPER BINDING TO S100A12: SUGGESTED ROLE IN OXIDATIVE MODIFICATION OF HUMAN LDL. ATHEROSCLEROSIS SUPP 2010. [DOI: 10.1016/s1567-5688(10)70544-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Hoppmann S, Steinbach J, Pietzsch J. Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. Int J Biochem Cell Biol 2009; 42:651-61. [PMID: 20025991 DOI: 10.1016/j.biocel.2009.12.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2009] [Revised: 12/09/2009] [Accepted: 12/09/2009] [Indexed: 11/25/2022]
Abstract
Increased plasma levels of S100 proteins and interaction of S100 proteins with receptor for advanced glycation end products (RAGE) have been associated with a number of disease states, including chronic inflammatory processes and atherosclerosis. However, data concerning the role of circulating S100 proteins in these pathologies in vivo are scarce and, furthermore, it is currently not known whether RAGE is the sole receptor for extracellular S100 proteins in vivo. We report a novel methodology using recombinant human S100 proteins radiolabelled with fluorine-18, particularly, (18)F-S100A12, in receptor binding studies and cellular association studies in vitro, and in dynamic small animal positron emission tomography (PET) studies in rats in vivo. Association to both human aortic endothelial cells and macrophages revealed specific binding of (18)F-S100A12 to RAGE, but, furthermore, provides evidence for interaction of (18)F-S100A12 to various scavenger receptors (SR). PET data showed temporary association of (18)F-S100A12 with tissues overexpressing RAGE (e.g., lung), and, moreover, accumulation of (18)F-S100A12 in tissues enriched in cells overexpressing SR (e.g., liver and spleen). Blockade of overall SR interaction by maleylated BSA (malBSA) clearly shows diminished in vivo association of (18)F-S100A12 to these tissues as well as a significant increment of the mean plasma residence time of (18)F-S100A12 (4.8+/-0.4 h vs. 2.3+/-0.3 h). The present approach first demonstrates that besides RAGE also scavenger receptors contribute to distribution, tissue association and elimination of circulating proinflammatory S100A12.
Collapse
Affiliation(s)
- Susan Hoppmann
- Institute of Radiopharmacy, Research Center Dresden-Rossendorf, P.O. Box 51 01 19, D-01314 Dresden, Germany
| | | | | |
Collapse
|
17
|
Hoppmann S, Haase C, Richter S, Pietzsch J. Expression, purification and fluorine-18 radiolabeling of recombinant S100 proteins--potential probes for molecular imaging of receptor for advanced glycation endproducts (RAGE) in vivo. Protein Expr Purif 2007; 57:143-52. [PMID: 18039581 DOI: 10.1016/j.pep.2007.10.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2007] [Revised: 09/27/2007] [Accepted: 10/12/2007] [Indexed: 11/16/2022]
Abstract
Data concerning the pathophysiological role of the interaction of circulating S100 proteins, a multigenic family of Ca(2+)-modulated proteins, with the receptor for advanced glycation endproducts (RAGE) in cardiovascular diseases, inflammatory processes, and tumorigenesis in vivo are scarce. One reason is the shortage of suitable radiotracer methods. We report a novel methodology using recombinant human S100A1, S100B, and S100A12 as potential probes for molecular imaging of this interaction. Therefore, human S100 proteins were cloned as GST fusion proteins in the bacterial expression vector pGEX-6P-1 and expressed in E. coli strain BL21. Purified recombinant human S100 proteins were radiolabeled with the positron emitter fluorine-18 ((18)F) by conjugation with N-succinimidyl-4-[(18)F]fluorobenzoate ([(18)F]SFB). The radiolabeled recombinant S100 proteins ((18)F-S100) were used in biodistribution experiments and small animal positron emission tomography (PET) studies in rats. The tissue-specific distribution of (18)F-S100 proteins in vivo correlated well with the anatomical localization of RAGE, e.g., in lungs and in the vascular system. These findings indicate circulating S100A1, S100B, and S100A12 proteins to be ligands for RAGE in rats in vivo. The approach allows the use of small animal PET and provides novel probes to delineate functional expression of RAGE under normal and pathophysiological conditions in rodent models of disease.
Collapse
Affiliation(s)
- Susan Hoppmann
- Department of Radiopharmaceutical Biology, Institute of Radiopharmacy, Research Center Dresden-Rossendorf, 01314 Dresden, Germany
| | | | | | | |
Collapse
|